Harvard Bioscience, Inc. (NASDAQ:HBIO) Stake Raised by AMH Equity Ltd

AMH Equity Ltd increased its position in shares of Harvard Bioscience, Inc. (NASDAQ:HBIO) by 4.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,500,000 shares of the medical instruments supplier’s stock after purchasing an additional 111,132 shares during the period. Harvard Bioscience makes up 5.2% of AMH Equity Ltd’s portfolio, making the stock its 6th largest holding. AMH Equity Ltd owned about 5.73% of Harvard Bioscience worth $5,275,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. State Street Corp increased its stake in Harvard Bioscience by 1.1% in the third quarter. State Street Corp now owns 717,387 shares of the medical instruments supplier’s stock worth $1,930,000 after purchasing an additional 7,763 shares during the period. Royce & Associates LP grew its holdings in shares of Harvard Bioscience by 0.7% in the third quarter. Royce & Associates LP now owns 1,451,450 shares of the medical instruments supplier’s stock worth $3,904,000 after purchasing an additional 10,000 shares during the last quarter. GSA Capital Partners LLP bought a new position in shares of Harvard Bioscience in the third quarter worth about $30,000. JPMorgan Chase & Co. increased its stake in Harvard Bioscience by 63.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 29,501 shares of the medical instruments supplier’s stock worth $79,000 after buying an additional 11,397 shares during the period. Finally, Avior Wealth Management LLC lifted its holdings in Harvard Bioscience by 1,118.1% during the 3rd quarter. Avior Wealth Management LLC now owns 14,569 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 13,373 shares in the last quarter. 80.87% of the stock is currently owned by institutional investors.

Harvard Bioscience Price Performance

Shares of HBIO stock opened at $0.89 on Thursday. The company has a market capitalization of $38.74 million, a P/E ratio of -2.69 and a beta of 1.25. The company’s 50-day simple moving average is $1.74 and its two-hundred day simple moving average is $2.25. Harvard Bioscience, Inc. has a one year low of $0.86 and a one year high of $4.70. The company has a debt-to-equity ratio of 0.52, a current ratio of 2.06 and a quick ratio of 0.91.

Harvard Bioscience Company Profile

Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.